Ascendiant Capital Starts PAVmed (PAVM) at Buy
Ascendiant Capital analyst Edward Woo initiates coverage on PAVmed (NASDAQ: PAVM) with a Buy rating and a price target of $5.00.
Shares of PAVmed closed at $1.82 yesterday.
You May Also Be Interested In
- UPDATE: Stephens Starts Enphase Energy (ENPH) at Overweight, 'Leading Microinverter Company'
- Morgan Stanley Starts Raytron Technology Co Ltd (688002:CH) at Overweight
- UPDATE: Stephens Starts First Solar (FSLR) at Overweight
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!